Armata Pharmaceuticals (ARMP) EBITDA Margin (2013 - 2020)

Armata Pharmaceuticals (ARMP) reported EBITDA Margin of 14806.45% for Q2 2020, down 25.21% sequentially from 11825.0% in Q4 2017.

Armata Pharmaceuticals (ARMP) EBITDA Margin (2013 - 2020) Analysis & Trends

Armata Pharmaceuticals (ARMP) has 6 years of EBITDA Margin data on file, last reported at 14806.45% in Q2 2020.

For the quarter ending Q2 2020, EBITDA Margin changed N/A year-over-year to 14806.45%; the trailing twelve-month figure through Jun 2020 stood at 17661.54% (changed N/A YoY), and the FY2017 full-year result was 14048.7%, down 505716.0% from the prior year.
EBITDA Margin fell to 14806.45% in Q2 2020, from 11825.0% in the prior quarter.
In the past five years, EBITDA Margin ranged from a high of 1963.16% in Q3 2017 to a low of 53927.27% in Q4 2016.
A 3-year average of 16465.83% and a median of 11748.28% in 2016 frame the typical range for EBITDA Margin.
Across the five-year window, EBITDA Margin slumped 5163040 bps in 2016 and surged 4210227 bps in 2017, its largest moves.
Tracing ARMP's EBITDA Margin over 3 years: stood at 53927.27% in 2016, then soared by 78 bps to 11825.0% in 2017, then decreased by 25 bps to 14806.45% in 2020.
Business Quant data shows ARMP's EBITDA Margin at 14806.45% in Q2 2020, 11825.0% in Q4 2017, and 1963.16% in Q3 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Armata Pharmaceuticals	191.29 Mn	186.49 Mn	-	-

Download Data